MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: ARPA-H
*Contractors & Awardees: ARPA-H
Thymmune Therapeutics
Organization & Developments: Thymmune Therapeutics
Parents
Thymmune Therapeutics
Children
*Specializes in developing cell therapies for the thymus, a small organ in the immune system that trains T-cells — which are critical to fighting infections and disease.
*Thymmune’s leading drug candidate, THY-100, is designed to treat congenital athymia, a rare and critical condition that causes infants to be born without a functioning thymus
2023: ARPA_H_Stem cell startup Thymmune lands $37M from Biden's ARPA-H for immune-rejuvenating therapies
Jumps
Finance & Acquisition: Thymmune Therapeutics
Key People: Thymmune Therapeutics